Cargando…

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

BACKGROUND: Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation, MEK inhibitors (MEKi) ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandez, Marta Llaurado, Dawson, Amy, Hoenisch, Joshua, Kim, Hannah, Bamford, Sylvia, Salamanca, Clara, DiMattia, Gabriel, Shepherd, Trevor, Cremona, Mattia, Hennessy, Bryan, Anderson, Shawn, Volik, Stanislav, Collins, Colin C., Huntsman, David G., Carey, Mark S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325847/ https://www.ncbi.nlm.nih.gov/pubmed/30636931 http://dx.doi.org/10.1186/s12935-019-0725-1

Ejemplares similares

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
por: Llaurado Fernandez, Marta, et al.
Publicado: (2022)

Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro
por: Correa, Rohann J. M., et al.
Publicado: (2015)

Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer
por: Buensuceso, Adrian, et al.
Publicado: (2022)

Gain-of-function p53(R175H) blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma
por: Haagsma, Jacob, et al.
Publicado: (2023)

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
por: Aslan, Ozlem, et al.
Publicado: (2018)

Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway
por: Wu, Dongdong, et al.
Publicado: (2019)

Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway
por: Niu, Chang-Chun, et al.
Publicado: (2014)

Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C
por: Kolendowski, Bart, et al.
Publicado: (2020)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma
por: Lin, Shibo, et al.
Publicado: (2013)

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
por: Cheasley, Dane, et al.
Publicado: (2022)

Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
por: Haas, Bodo, et al.
Publicado: (2018)

Down-regulation of TRIB3 inhibits the progression of ovarian cancer via MEK/ERK signaling pathway
por: Wang, Shuang, et al.
Publicado: (2020)

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma
por: Lin, Shitong, et al.
Publicado: (2020)

Comprehensive analysis of the expression of sodium/potassium-ATPase α subunits and prognosis of ovarian serous cystadenocarcinoma
por: Huang, Wei, et al.
Publicado: (2020)

The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer
por: Zhu, Tingting, et al.
Publicado: (2020)

MiR-155-5p suppresses SOX1 to promote proliferation of cholangiocarcinoma via RAF/MEK/ERK pathway
por: Wang, Da, et al.
Publicado: (2021)

High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation
por: Bourgeois, Danielle L., et al.
Publicado: (2015)

Benzimidazoisoquinoline derivatives inhibit glioblastoma cell proliferation through down-regulating Raf/MEK/ERK and PI3K/AKT pathways
por: Zhang, Ya-Jun, et al.
Publicado: (2018)

UBTF facilitates melanoma progression via modulating MEK1/2-ERK1/2 signalling pathways by promoting GIT1 transcription
por: Zhang, Jian, et al.
Publicado: (2021)

SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals
por: She, Kelin, et al.
Publicado: (2019)

Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response
por: Zhang, Han, et al.
Publicado: (2021)

Induced Second Trimester Abortion and Associated Factors at Debre Markos Referral Hospital: Cross-Sectional Study
por: Tesfaye, Bekele, et al.
Publicado: (2020)

Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer
por: Greenaway, James B., et al.
Publicado: (2016)

LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway
por: Cui, Ran, et al.
Publicado: (2019)

PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3
por: Soriano, Amata Amy, et al.
Publicado: (2019)

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017)

Rapidly Changing Serous Detachment During BRAF and MEK Inhibitor Therapy
por: Agata, Chisato, et al.
Publicado: (2021)

Circ_0032821 acts as an oncogene in cell proliferation, metastasis and autophagy in human gastric cancer cells in vitro and in vivo through activating MEK1/ERK1/2 signaling pathway
por: Jiang, Yuanyuan, et al.
Publicado: (2020)

A descriptive analysis of health practices, barriers to healthcare and the unmet need for cervical cancer screening in the Lower Napo River region of the Peruvian Amazon
por: Collins, Joseph H, et al.
Publicado: (2019)

EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells
por: Zhang, Yingdong, et al.
Publicado: (2010)

The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR
por: Tan, Biqin, et al.
Publicado: (2020)

Lattice complex assembled by noncompetitive anti-EGFR antibodies regulates actin cytoskeletal reorganization
por: Huang, Dianshuai, et al.
Publicado: (2020)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma
por: Liu, Tao, et al.
Publicado: (2021)

Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway
por: Li, Piao, et al.
Publicado: (2022)

Serous Retinopathy Associated With Combination MEK and Fibroblast Growth Factor Receptor Inhibitor
por: Day, H. Russell, et al.
Publicado: (2023)

Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients
por: Kim, Yoonjung, et al.
Publicado: (2019)

Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration
por: Duan, Hongying, et al.
Publicado: (2014)

CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway
por: Yuan, Wanqiong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8e507tt0u5863f6tjobvs4hm9u